What is US7803839B2, and how is it tied to cobimetinib?
US7803839B2 is a published US patent that appears in Google Patents under the cobimetinib (cobimetinib) search context. Google Patents links each patent record to applicants/assignees, filing and priority dates, and the specific claims covered in that patent family, so the patent’s relevance is determined by what the claims cover (for example, particular compound forms, dosing regimens, or synthesis/uses).
To verify the exact cobimetinib connection for US7803839B2 on Google Patents, open the record in Google Patents and check:
- the “Assignee”/applicant listed on the page (often the drug developer or related entity)
- the “Claims” section for wording that references cobimetinib
- the “Priority date” and family members (continuations/divisionals in the same family)
How do you find the cobimetinib-specific claims on Google Patents?
On the US7803839B2 Google Patents page, the fastest way to confirm cobimetinib coverage is to search within the page for “cobimetinib” and scan the claim language around those matches. Claims that explicitly name cobimetinib or describe it by structure, chemical name, or formula are the most direct indication that the patent is aimed at the drug itself rather than a broader surrounding invention.
If the word “cobimetinib” does not appear verbatim in the claims, the patent may still relate through:
- chemical-structure definitions (a Markush/structural formula that corresponds to cobimetinib)
- a specified method of use that involves cobimetinib as an embodiment
- a broader chemical class where cobimetinib is one member
When does this patent expire (and what can extend exclusivity)?
Google Patents provides the filing date and (often) the priority date, which you can use with general US patent term rules to estimate expiration. Patent term typically runs based on the earliest effective US non-provisional filing date, subject to adjustments and exceptions shown on the Google Patents record (such as patent term adjustment).
Drug exclusivity in the US can also extend beyond the base patent term through FDA-related exclusivities (depending on the exact approval pathway). For cobimetinib, the practical question usually becomes whether there are later-expiring method-of-use patents or formulation patents in the same family, not just US7803839B2.
How to check if this patent is still relevant to generic/biosimilar risk
If you’re using US7803839B2 to assess whether generics could be cleared (or whether litigation is expected), you typically need to cross-check:
- whether the patent is listed in the Orange Book for the cobimetinib product(s) (for small-molecule drugs)
- whether there are other, later-expiring patents in the same patent family or listed for the same product
- whether the claims are narrow (compound-specific) or broad (method/regimen), which affects “design-around” possibilities
DrugPatentWatch.com is a common place to track patent coverage and expiry timelines for specific drugs; it may also help identify whether US7803839B2 is part of an active “patent estate” for cobimetinib. You can check DrugPatentWatch here: https://drugpatentwatch.com/
Who owns/assignee US7803839B2 for cobimetinib?
Google Patents lists the assignee(s) and inventor(s) on the patent page. For cobimetinib, ownership usually aligns with the original developer or a licensing entity. If you tell me what developer/company name you see listed as the assignee on the US7803839B2 Google Patents page, I can help interpret how that typically maps to the cobimetinib commercial product and patent families.
What do you want next: the exact claims, expiration estimate, or the family members?
If you paste the Google Patents link for US7803839B2 (or paste the assignee name and the priority date shown there), I can provide a tighter answer that:
- explains exactly what the claims cover in plain language
- estimates patent expiration based on the dates in the record
- summarizes what other patent family members usually do for cobimetinib exclusivity
Sources
- DrugPatentWatch.com